Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stentys SAS

This article was originally published in Start Up

Executive Summary

The design of currently marketed stents is not optimal in treating stenosis in or next to coronary bifurcations. Stentys, founded by noted cardiologist and entrepreneur Jacques Séguin, MD, PhD, aims to improve on outcomes while keeping things simple. It believes its bifurcation stent will be as easy for cardiologists to use as conventional stents, but that its novel design will provide superior clinical results by enabling full opening and scaffolding of the side branch.

You may also be interested in...



Stentys' IPO: European Public Markets Opening For Device Companies?

The emerging device companies that have been hardest hit by the economic woes of the past couple of years have been those looking for later-stage financing. These companies face venture investors who are either unwilling or unable to invest in late-stage deals, while also confronting an IPO market that largely remains closed to them, particularly in the US. In Europe, however, that may be changing, most notably in France, where Stentys SAS, which is developing stents to treat acute myocardial infarctions, recently became the second device company to successfully go public this year.

Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?

Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem with a device that's a new version of an old idea, reversing current protocol to treat the side branch first.

Tryton Medical: Going Against the Flow in Bifurcated Stents

Many device companies, large and small, have tried unsuccessfully to come up with a stent to treat bifurcated lesions, primarily by focusing on treating the main vessel. Tryton is taking a different approach: using a bare-metal device designed to treat the side branch. The company believes this contrarian strategy pairs perfectly with current drug-eluting stents, making them an ideal acquisition target for a large CV company.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel